Results of Paraffin Immunohistochemistry
| Case . | BCL-2* . | CD20† . | Light Chain Restriction‡ . | Ki671-153 . | ||
|---|---|---|---|---|---|---|
| F . | IF . | F . | IF . | |||
| 1 | + | +++ | κ | κ | +++ | + |
| 2 | + | +++ | λ | λ | +++ | +/− |
| 3 | + | +++ | κ | κ | ++ | +/− |
| 4 | + | ++ | λ | λ | ++ | +/− |
| 5 | + | ++ | λ | λ | ++ | +/− |
| 6 | + | +++ | λ | λ | ++ | +/− |
| 7 | + | ++ | λ | κ, λ | ++ | − |
| 8 | + | + | κ | − | + | − |
| 9 | + | ++ | us | us | us | us |
| 10 | + | +++ | λ | κ, λ | ++ | + |
| 11 | + | +++ | λ | κ, λ | ++ | + |
| 12 | + | +++ | − | − | +++ | +/− |
| 13 | + | ++ | κ | κ | ++ | +/− |
| 14 | + | +++ | κ | κ | +++ | +/− |
| 15 | + | ++ | λ | κ, λ | +++ | +/− |
| 16 | + | +++ | κ | κ | ++ | +/− |
| 17 | + | ++ | κ | κ | ++ | ++ |
| 18 | + | +++ | κ | κ | ++ | +/− |
| 19 | + | +++ | κ | κ | ++ | +/− |
| 20 | + | ++ | κ | κ | +++ | + |
| 21 | + | ++ | κ | κ | ++ | + |
| 22 | + | +++ | us | us | +++ | + |
| 23 | + | ++ | κ | κ | ++ | + |
| 24 | + | + | κ | − | + | − |
| 25 | + | ++ | λ | PCλ | us | us |
| 26 | + | ++ | λ | λ | + | − |
| 27 | + | ++ | us | us | ++ | + |
| 28 | + | ++ | κ | κ | ++ | +/− |
| 29 | + | ++ | κ | κ | ++ | +/− |
| 30 | + | + | κ | − | ++ | + |
| Case . | BCL-2* . | CD20† . | Light Chain Restriction‡ . | Ki671-153 . | ||
|---|---|---|---|---|---|---|
| F . | IF . | F . | IF . | |||
| 1 | + | +++ | κ | κ | +++ | + |
| 2 | + | +++ | λ | λ | +++ | +/− |
| 3 | + | +++ | κ | κ | ++ | +/− |
| 4 | + | ++ | λ | λ | ++ | +/− |
| 5 | + | ++ | λ | λ | ++ | +/− |
| 6 | + | +++ | λ | λ | ++ | +/− |
| 7 | + | ++ | λ | κ, λ | ++ | − |
| 8 | + | + | κ | − | + | − |
| 9 | + | ++ | us | us | us | us |
| 10 | + | +++ | λ | κ, λ | ++ | + |
| 11 | + | +++ | λ | κ, λ | ++ | + |
| 12 | + | +++ | − | − | +++ | +/− |
| 13 | + | ++ | κ | κ | ++ | +/− |
| 14 | + | +++ | κ | κ | +++ | +/− |
| 15 | + | ++ | λ | κ, λ | +++ | +/− |
| 16 | + | +++ | κ | κ | ++ | +/− |
| 17 | + | ++ | κ | κ | ++ | ++ |
| 18 | + | +++ | κ | κ | ++ | +/− |
| 19 | + | +++ | κ | κ | ++ | +/− |
| 20 | + | ++ | κ | κ | +++ | + |
| 21 | + | ++ | κ | κ | ++ | + |
| 22 | + | +++ | us | us | +++ | + |
| 23 | + | ++ | κ | κ | ++ | + |
| 24 | + | + | κ | − | + | − |
| 25 | + | ++ | λ | PCλ | us | us |
| 26 | + | ++ | λ | λ | + | − |
| 27 | + | ++ | us | us | ++ | + |
| 28 | + | ++ | κ | κ | ++ | +/− |
| 29 | + | ++ | κ | κ | ++ | +/− |
| 30 | + | + | κ | − | ++ | + |
See Materials and Methods for details of semiquantitative assessment of immunohistochemical reactivity.
Abbreviations: F, follicular component; IF, interfollicular component; us, immunohistochemical staining was unsatisfactory.
Bcl-2 immunostaining, (+), tumor expresses bcl-2; (−), tumor is bcl-2 negative.
CD20 immunostaining, the extent of CD20 positive interfollicular B cells; (+) minimal, (++) moderate, (+++) prominent.
Light chain restriction, κ, Ig κ light chain restriction; λ, Ig λ light chain restriction; κ and λ, no light chain restriction, polyclonal; (−) no light chain staining; PCλ, plasma cells show λ light chain restriction.
MIB-1 immunostaining, +++, ++, +, +/−, − indicate the number of cells expressing Ki67 antigen in follicular and interfollicular zones.